---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211572"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:38:31.939361+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria

## Summary
- VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.
- At high and middle doses, VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20.
- For 11 unique serotypes, all three doses met superiority criteria.
- Company selects VAX-31 for adult Phase 3; plans to initiate pivotal study by mid-2025 with topline data in 2026.
- Also plans VAX-31 infant Phase 2 study in Q1 2025.

## SEC filing metadata
- accession: 0001193125-24-211572
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312524211572/0001193125-24-211572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312524211572/d813919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211572
- JSON: https://secwatch.observer/filing/0001193125-24-211572.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.